MiRXES Sees China as Crucial Market for Growth
PorAinvest
viernes, 23 de mayo de 2025, 12:20 am ET1 min de lectura
MIR--
The partnership will operate under the unified brand VRR Life Sciences, a Unicon Company, and is a significant step in Unicon's broader vision of building an integrated global platform for validation and regulatory excellence. The collaboration combines Unicon's strong U.S. market presence with VRR's extensive CSV expertise and offshore delivery model, aiming to provide enhanced value through speed, cost-efficiency, and quality assurance.
Ravi Kollipara, CEO of Unicon Pharma, stated, "Our clients are operating in a time of regulatory transformation, with increasing expectations around data integrity, digital systems, and global compliance. With VRR Life Sciences joining our platform, we are not only expanding our technical depth—we are reinforcing our ability to deliver high-quality results at scale."
Gireesh T., CEO of VRR Life Sciences, commented, "Joining with Unicon allows us to bring our proven methods to new markets while aligning with a partner who shares our values and standards. It's an important step forward for our team and the clients we'll serve together."
VRR Life Sciences, a Unicon Company, will focus on enterprise-level CSV projects, data integrity remediation, and IT compliance initiatives, helping life sciences organizations reduce risk, enhance quality, and accelerate delivery across the development lifecycle.
This partnership follows Unicon's 2024 collaboration with CORE to enhance CQV services and aligns with its broader vision of building an integrated global platform for validation and regulatory excellence.
For more information, visit:
- Unicon Pharma Inc: http://www.uniconpharma.com
- VRR Life Sciences: http://www.vrrlifesciences.com
[1] https://www.morningstar.com/news/pr-newswire/20250521ny54231/unicon-pharma-announces-strategic-partnership-with-vrr-life-sciences-to-expand-global-csv-capabilities-and-support-digital-transformation-in-life-sciences
VRAR--
MiRXES, a Singapore-based life sciences company, plans to expand its presence in China, which it sees as an important market. The company has already established partnerships with Chinese hospitals and plans to increase its sales and marketing efforts in the country. MiRXES aims to tap into China's growing demand for cancer diagnostics and treatment, and is optimistic about the market's potential for growth.
SOUTH PLAINFIELD, N.J., May 21, 2025 — Unicon Pharma, a leading provider of compliance, validation, and workforce solutions for the life sciences industry, has announced a strategic partnership with VRR Life Sciences. This collaboration aims to enhance Unicon's global capabilities in Computer System Validation (CSV) and support digital transformation in the life sciences sector.The partnership will operate under the unified brand VRR Life Sciences, a Unicon Company, and is a significant step in Unicon's broader vision of building an integrated global platform for validation and regulatory excellence. The collaboration combines Unicon's strong U.S. market presence with VRR's extensive CSV expertise and offshore delivery model, aiming to provide enhanced value through speed, cost-efficiency, and quality assurance.
Ravi Kollipara, CEO of Unicon Pharma, stated, "Our clients are operating in a time of regulatory transformation, with increasing expectations around data integrity, digital systems, and global compliance. With VRR Life Sciences joining our platform, we are not only expanding our technical depth—we are reinforcing our ability to deliver high-quality results at scale."
Gireesh T., CEO of VRR Life Sciences, commented, "Joining with Unicon allows us to bring our proven methods to new markets while aligning with a partner who shares our values and standards. It's an important step forward for our team and the clients we'll serve together."
VRR Life Sciences, a Unicon Company, will focus on enterprise-level CSV projects, data integrity remediation, and IT compliance initiatives, helping life sciences organizations reduce risk, enhance quality, and accelerate delivery across the development lifecycle.
This partnership follows Unicon's 2024 collaboration with CORE to enhance CQV services and aligns with its broader vision of building an integrated global platform for validation and regulatory excellence.
For more information, visit:
- Unicon Pharma Inc: http://www.uniconpharma.com
- VRR Life Sciences: http://www.vrrlifesciences.com
[1] https://www.morningstar.com/news/pr-newswire/20250521ny54231/unicon-pharma-announces-strategic-partnership-with-vrr-life-sciences-to-expand-global-csv-capabilities-and-support-digital-transformation-in-life-sciences
Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios